Last reviewed · How we verify
GC5107
GC5107 is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that enhances insulin secretion and reduces glucagon release to lower blood glucose levels.
GC5107 is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that enhances insulin secretion and reduces glucagon release to lower blood glucose levels. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | GC5107 |
|---|---|
| Also known as | GCC 10% IGIV, Immune Globulin Intravenous (Human), 10% Liquid, IGIV, Immune globulin intravenous (human) solution, 10% liquid |
| Sponsor | GC Biopharma Corp |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Biologic |
| Therapeutic area | Endocrinology |
| Phase | Phase 3 |
Mechanism of action
GC5107 binds to and activates GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion. It also suppresses glucagon secretion and slows gastric emptying, leading to improved glycemic control. The long-acting formulation allows for less frequent dosing compared to shorter-acting GLP-1 agonists.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Gastrointestinal disorders
Key clinical trials
- Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency (PHASE3)
- Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GC5107 CI brief — competitive landscape report
- GC5107 updates RSS · CI watch RSS
- GC Biopharma Corp portfolio CI